Eli Lilly announced positive Phase 3 maintenance data for orforglipron, an oral GLP‑1 receptor agonist, showing it helped patients retain weight loss after prior treatment with injectable incretin therapies. The Attain‑Maintain trial met primary and all key secondary endpoints at 52 weeks versus placebo in participants who had completed an initial weight‑loss regimen. The trial re‑randomized patients who had received Wegovy or Zepbound in an earlier study; Lilly reported orforglipron superior to placebo for weight maintenance and outlined plans for regulatory review. The program benefits from a fast‑track national priority voucher that could speed FDA review. The maintenance indication could expand the oral drug’s commercial appeal, offering an alternative for patients seeking to sustain weight loss without long‑term injectable therapy.